GNS Healthcare is a healthcare analytics company, founded in 2000 and based in Kendall Square, Cambridge, MA. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment and cost challenges. They are a multi-disciplinary group of physicists, actuaries, geneticists, engineers, business people, and computer scientists, passionate about extracting the evidence of what works in healthcare and for whom.
HQCambridge, US
Size (employees)122 (est)
GNS Healthcare was founded in 2000 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at GNS Healthcare

Colin Hill

Colin Hill

CEO & President & Chairman and Co-Founder
Mark Pottle

Mark Pottle

Bruce Church

Bruce Church

Chief Mathematics Officer
Iya Khalil

Iya Khalil

Executive Vice President and Founder
Benjamin Bielak

Benjamin Bielak

Chief Information Officer
Show more

GNS Healthcare Office Locations

GNS Healthcare has offices in Cambridge and Austin
Cambridge, US (HQ)
196 Broadway
Cambridge, US (HQ)
196 Broadway
Austin, US
701 Brazos St
Show all (3)
Report incorrect company information

GNS Healthcare Financials and Metrics

Summary Metrics

Founding Date


GNS Healthcare total Funding

$49.1 m

GNS Healthcare latest funding size

$6 m

Time since last funding

a year ago

GNS Healthcare investors

GNS Healthcare's latest funding round in August 2017 was reported to be $6 m. In total, GNS Healthcare has raised $49.1 m
Show all financial metrics
Report incorrect company information

GNS Healthcare Online and Social Media Presence

Embed Graph
Report incorrect company information

GNS Healthcare News and Updates

GNS Healthcare Presents Results of Metastatic Colorectal Cancer Collaboration with the Alliance for Clinical Trials in Oncology at ESMO 2018

CAMBRIDGE, Mass., Oct. 22, 2018 /PRNewswire/ -- GNS Healthcare (GNS), a leading precision medicine company, presented results in metastatic colorectal cancer this week from their most recent collaboration with the Alliance for Clinical Trials in Oncology (Alliance) at the ESMO 2018...

GNS Healthcare Co-Founder and Chief Commercial Officer Iya Khalil Named to INC Magazine's List of Top Female Founders for 2018

CAMBRIDGE, Mass., Oct. 5, 2018 /PRNewswire/ -- Each October, INC Magazine chooses leading women pioneers, entrepreneurs and innovators to profile in its annual Women Entrepreneurs issue. In their 2018 issue, GNS Co-Founder and Chief Commercial Officer Iya Khalil, PhD was profiled as one...

GNS Healthcare Names Healthcare Analytics Executive David Gascoigne as Chief Operating Officer

CAMBRIDGE, Mass., Oct. 3, 2018 /PRNewswire/ -- GNS Healthcare (GNS), a leading precision medicine company, has tapped data analytics veteran David Gascoigne as its Chief Operating Officer. Gascoigne has two decades of experience scaling and leading data analytics businesses in the...

Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in Metastatic Colorectal Cancer

CAMBRIDGE, Mass., Sept. 6, 2018 /PRNewswire/ -- GNS Healthcare (GNS), a leading precision medicine company, announced a cross-industry partnership with Amgen and the Alliance for Clinical Trials in Oncology (Alliance) that will apply causal artificial intelligence (AI) and simulation to...

GNS Healthcare Taps Technology Leader as CTO to Drive Productization of Causal AI Platform

CAMBRIDGE, Mass., Aug. 22, 2018 /PRNewswire/ -- GNS Healthcare (GNS), a leading precision medicine company, announced the hiring of veteran software executive Scott McKay as Chief Technology Officer. McKay brings over 25 years of hands-on experience in software development, including his...

The ALS Association Partners with GNS Healthcare to Apply AI to Accelerate Answer ALS Research

WASHINGTON and CAMBRIDGE, Mass., July 31, 2018 /PRNewswire/ -- The ALS Association is providing new funding to allow GNS Healthcare to use artificial intelligence (AI) to create a comprehensive disease model to advance research into ALS. GNS Healthcare will use its powerful machine...
Show more
Report incorrect company information

GNS Healthcare Blogs

Unstructured Data: Joining the Healthcare Party

The U. S. healthcare industry now produces an estimated 1.2 billion clinical care documents a year. Within those documents is an amazing amount of detail on an individual patient’s care plan, medical history and overall health.  So why is this type of data, not often touted, important? W…

Why We Should Be Celebrating Women Scientists for the Superstars They Are

Earlier this month, two prominent scientists were announced as winners for The Nobel Prize. They also happened to be women. Frances Arnold of the U.S. received the award for Chemistry and Donna Strickland of Canada earned her award in Physics. While the names of the Nobel Prize winners …

Tracking Digital Health Innovations: Another Step Toward Personalized Medicine

Do you fasten your Fitbit, smartwatch or other wearable device onto your wrist every morning and diligently track the number of steps taken or miles biked throughout the day? Perhaps you use an app on your smartphone to analyze your sleep patterns or as a reminder to take a vitamin or a …

The Promise and the Power of In Silico Clinical Trials

Clinical leaders at Dana-Farber Cancer Institute for Neuro-Oncology were becoming more frustrated with the lack of treatment options for patients suffering from glioblastoma (GBM). The aggressive form of brain cancer, which recently claimed the life of Senator John McCain, is one of the …

The Promise of Precision Medicine is Not Misleading, It’s Just Beginning

Last week, an op-ed was published in the New York Times that asked an important question: Are patients being misled by the promise of precision medicine? The article, which focused on the treatment of various forms of cancer, posited that the successes achieved through precision medicine…

How AI is Aiding Discoveries in Rare Disease Research

The Orphan Drug Act of 1983 defined a rare disease as one that affects less than 200,000 people. According to the NIH National Center for Advancing Translational Sciences, there are now 7,000 such diseases afflicting between 25-30 million people in the U. S. and an estimated 350 million …
Show more

GNS Healthcare Company Life and Culture

Report incorrect company information